Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Fred Yang
ResearcherPublications, citations & collaboration network
Fred Yang is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 23 works, 1,049 citations, an h-index of 10 and an i10-index of 10.
23
Works
1,049
Citations
10
h-index
10
i10-index
IDs:OpenAlex
How has Fred Yang's publication output changed over time?
ScholarIQpublication output · 2009–2018
Output grew0% over the shown period — from 2 works in 2009 to 2 in 2018.
2
4
1
1
2
20092014201520172018
What are the most-cited papers on Fred Yang?
ScholarIQmost cited works
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Julio Rosenstock, Jane E.B. Reusch, Mark Bush, Fred Yang, Murray Stewart, for the Albiglutide Study Group
Diabetes Care. 2009237 CitationsOPEN ACCESS
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Bo Åhrén, Susan Johnson, Murray Stewart, Deborah T. Cirkel, Fred Yang, Caroline Perry, Mark N. Feinglos
Diabetes Care. 2014227 Citations
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Julio Rosenstock, Vivian Fonseca, Jorge Luiz Gross, Robert E. Ratner, Bo Åhrén, Francis C. C. Chow, Fred Yang, Diane Miller, Susan Johnson, Murray Stewart, Lawrence A. Leiter
Diabetes Care. 2014206 Citations
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Michael A. Nauck, Murray Stewart, Christopher Perkins, Angela R. Jones-Leone, Fred Yang, Caroline Perry, Rickey R. Reinhardt, Marc Rendell
Diabetologia. 2015122 CitationsOPEN ACCESS
Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
Lawrence A. Leiter, Molly C. Carr, Murray Stewart, Angela R. Jones-Leone, Rhona Scott, Fred Yang, Yehuda Handelsman
Diabetes Care. 201493 Citations
Related on ScholarIQ
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Paper
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Paper
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Paper
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Paper
Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
Paper
Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
Paper